Dublin, Jan. 26, 2017 -- Research and Markets has announced the addition of the "Implantable Infusion Pumps Market Analysis & Trends- Application (Cancer Treatment, Cancer Pain, Noncancer Pain, Spasticity, Analgesia, Mixed Sarcoma and Skin Cancers, Gastric Cancer and Diabetes Mellitus) - Forecast to 2025" report to their offering.
The Global Implantable Infusion Pumps Market is poised to grow at a CAGR of around 6.3% over the next decade to reach approximately $14.33 billion by 2025.
Some of the prominent trends that the market is Chemotherapy for cancer patients, Surge for near-physiologic programmable method of insulin delivery, Increase in device based drug delivery technologies and Growth Opportunities/Investment Opportunities.
Based on Application the market is categorized into Cancer Treatment, Spasticity, Analgesia and Diabetes Mellitus. The Cancer Treatment segment is further divided as Cancer Pain, Noncancer Pain, Mixed Sarcoma and Skin Cancers and Gastric Cancer.
This industry report analyzes the global markets for Implantable Infusion Pumps across all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025.
The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors.
Key Topics Covered:
1 Market Outline
2 Executive Summary
3 Market Overview
3.1 Current Trends
3.1.1 Chemotherapy for cancer patients
3.1.2 Surge for near-physiologic programmable method of insulin delivery
3.1.3 Increase in device based drug delivery technologies
3.1.4 Growth Opportunities/Investment Opportunities
3.2 Drivers
3.3 Constraints
3.4 Industry Attractiveness
4 Implantable Infusion Pumps Market, By Application
4.1 Cancer Treatment
4.1.1.1 Cancer Pain
4.1.1.2 Noncancer Pain
4.1.1.3 Mixed Sarcoma and Skin Cancers
4.1.1.4 Gastric Cancer
4.2 Spasticity
4.3 Analgesia
4.4 Diabetes Mellitus
5 Implantable Infusion Pumps Market, By Geography
6 Key Player Activities
6.1 Acquisitions & Mergers
6.2 Agreements, Partnerships, Collaborations and Joint Ventures
6.3 Product Launch & Expansions
6.4 Other Activities
7 Leading Companies
7.1 Alnylam Pharmaceuticals, Inc.
7.2 Debiotech S.A.
7.3 Delpor, Inc.
7.4 Eksigent Technologies, LLC
7.5 Eli Lilly and Company
7.6 Flowonix Medical, Inc.
7.7 FluidSynchrony, LLC
7.8 Intarcia Therapeutics, Inc.
7.9 Medallion Therapeutics, Inc.
7.10 Nano Precision Medical
7.11 Pharmaco-Kinesis Corporation
7.12 University of Southern California Company
7.13 Halyard Health
7.14 Codman & Shurtleff
For more information about this report visit http://www.researchandmarkets.com/research/sm2s9p/implantable
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Infusions and Injectables , Needles and Syringes , Endocrinology , Dermatological Drugs


Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Washington Post Publisher Will Lewis Steps Down After Layoffs
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 



